XDEMVY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XDEMVY (XDEMVY).
XDEMVY (lotilaner ophthalmic solution) is a gamma-aminobutyric acid (GABA)-gated chloride channel antagonist. It inhibits the GABA-gated chloride channels in Demodex mites, leading to paralysis and death of the mites.
| Metabolism | Lotilaner is metabolized via cytochrome P450 (CYP) enzymes, primarily CYP3A4, and to a lesser extent CYP2C9 and CYP2C19. |
| Excretion | Primary renal excretion as unchanged drug and metabolites; ~70% in urine. Biliary/fecal excretion accounts for ~25%. |
| Half-life | Terminal elimination half-life of approximately 4-6 hours; clinically, steady-state is reached within 24-36 hours. |
| Protein binding | Approximately 90% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.35 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Oral bioavailability is approximately 85%; food may delay absorption but does not affect extent. |
| Onset of Action | Orally administered; onset of clinical effect occurs within 30-60 minutes. |
| Duration of Action | Duration of action is approximately 4-8 hours, based on pharmacodynamic response and dosing interval. |
1 drop in each eye once daily in the evening for 6 weeks.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment is recommended for patients with renal impairment. |
| Liver impairment | No dosage adjustment is recommended for patients with hepatic impairment. |
| Pediatric use | Safety and efficacy have not been established in pediatric patients. |
| Geriatric use | No dosage adjustment is recommended based on age; clinical studies included patients ≥65 years, and no overall differences in safety or efficacy were observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XDEMVY (XDEMVY).
| Breastfeeding | Unknown if excreted in human milk. No data on M/P ratio. Caution advised; consider developmental benefits of breastfeeding vs potential drug exposure. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no teratogenic effects were observed at exposures up to 5 times the human exposure at the recommended ophthalmic dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to lotilaner or any component of the formulation."]
| Precautions | ["Contains preservative benzalkonium chloride, which may cause eye irritation and is adsorbable by soft contact lenses. Patients should remove contact lenses prior to administration and wait at least 15 minutes before reinserting.","Use with caution in patients with known hypersensitivity to any component of the product.","Not for injection. For topical ophthalmic use only."] |
Loading safety data…
| No specific monitoring required beyond routine prenatal care. |
| Fertility Effects | No fertility studies conducted; based on mechanism of action (peripheral vasoconstrictor), no anticipated impact on fertility. |